athenahealth, Inc. Reports First Quarter Fiscal Year 2014 Results
Q1 2014 Financial Results
| • | 30% Revenue Growth Over First Quarter of 2013 |
| • | Non-GAAP Adjusted Operating Income of $8.7 million |
| • | GAAP Net Loss of $8.1 million, or $0.21 Per Diluted Share |
| • | Non-GAAP Adjusted Net Income of $4.4 million, or $0.12 Per Diluted Share |
WATERTOWN, MA – April 17, 2014 - athenahealth, Inc. (NASDAQ: ATHN) (“athenahealth” or “we”), a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, today announced financial and operational results for the first quarter of fiscal year 2014. We will conduct a conference call tomorrow, Friday, April 18, 2014, at 8:00 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.
| • | Total revenue for the three months ended March 31, 2014 was $163.0 million, compared to $125.6 million in the same period last year, an increase of 30%. |
| ◦ | Excluding revenue from Epocrates-branded services of $10.6 million and other revenue of $4.2 million, revenue from athenahealth-branded services was $148.2 million, an increase of 23% over $120.1 million for the three months ended March 31, 2013. |
“We made significant progress in the first quarter of 2014 as we continued to invest, innovate, and reshape the caregiver experience,” said Jonathan Bush, athenahealth’s chairman and chief executive officer. “By making targeted investments in growth, innovation, and facilities, we are positioning the company to continue on our 30 percent growth trajectory. We continue to transform and grow our network with a keen eye on our vision of building an information backbone that helps make health care work as it should. The athenahealth team is focused on building the services that caregivers trust, by providing simplified solutions that enable them to thrive despite a rapidly changing health care landscape. We remain committed to further advancing the state of the industry, proactively seeking ways to increase accountability and disrupt the status quo.”
| • | For the three months ended March 31, 2014, Non-GAAP Adjusted Gross Margin was 59.8%, down slightly from 60.4% in the same period last year. |
| • | For the three months ended March 31, 2014, Non-GAAP Adjusted Operating Income was $8.7 million, or 5.4% of total revenue, compared to Non-GAAP Adjusted Operating Income of $9.4 million, or 7.5% of total revenue, in the same period last year. |
| • | For the three months ended March 31, 2014, GAAP Net Loss was $8.1 million, or $0.21 per diluted share, compared to GAAP Net Income of $0.7 million, or $0.02 per diluted share, in the same period last year. |
| • | For the three months ended March 31, 2014, Non-GAAP Adjusted Net Income was $4.4 million, or $0.12 per diluted share, compared to $14.2 million, or $0.38 per diluted share, in the same period last year. |
| ◦ | For 2014, we are using a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income could result in a volatile GAAP effective tax rate. |
1
If this approach had been used in 2013, our Q1 2013 Non-GAAP Adjusted Net Income per Diluted Share would have been $0.15 instead of $0.38.
“We are pleased with the progress we made in the first quarter to deliver on our full year growth targets,” said Tim Adams, athenahealth’s chief financial officer. “We see strong signs of positive momentum; we grew our core physician network by 31%, we expanded athenaClinicals into our enterprise segment, and we signed our first athenaCoordinator Enterprise clients. We will continue to invest at a pace that keeps us in front of the enormous market opportunity to help caregivers proactively address the inevitable changes in health care.”
Use of Non-GAAP Financial Measures
In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we may use or discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investors section of our web site at www.athenahealth.com.
Conference Call Information
To participate in our live conference call and webcast, please dial 877-853-5645 (or 408-940-3868 for international calls) using conference code No. 11893618, or visit the Investors section of our website at www.athenahealth.com. A replay will be available for one week following the conference call at 855-859-2056 (and 404-537-3406 for international calls) using conference code No. 11893618. A webcast replay will also be archived on our website.
About athenahealth
athenahealth is a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination. athenahealth’s mission is to be caregivers’ most trusted service, helping them do well doing the right thing. For more information, please visit www.athenahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements reflecting management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; statements regarding the benefits of our service offerings and demands for our service offerings; statements regarding the potential expansion of our network, including into the enterprise segment; statements regarding our market opportunity; statements regarding changes in the health care industry, including an increased emphasis on cloud-based services for medical providers, and our positioning in regard to those changes; and statements found under our “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” section of this release. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: our fluctuating operating results; our variable sales and implementation cycles, which may result in
2
fluctuations in our quarterly results; risks associated with the acquisition and integration of companies and new technologies to achieve expected synergies, including those related to our ability to successfully integrate the services and offerings of Epocrates and realize the expected benefits; risks associated with our ability to realize the expected benefits from the purchase of the Arsenal on the Charles campus in Watertown, Massachusetts; risks associated with our expectations regarding our ability to maintain profitability; the impact of increased sales and marketing expenditures, including whether increased expansion in revenues is attained and whether impact on margins and profitability is longer term than expected; changes in tax rates or exposure to additional tax liabilities; the highly competitive industry in which we operate and the relative immaturity of the market for our service offerings; and the evolving and complex governmental and regulatory compliance environment in which we and our clients operate. Forward-looking statements may often be identified with words such as “we expect”, “we anticipate”, “upcoming” or similar indications of future expectations. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by us, please see the disclosures contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at www.athenahealth.com and on the SEC’s website at www.sec.gov.
Contact Info:
Dana Quattrochi
athenahealth, Inc. (Investors)
investorrelations@athenahealth.com
(617) 402-1329
Holly Spring
athenahealth, Inc. (Media)
media@athenahealth.com
(617) 402-1631
3
athenahealth, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except per share amounts)
| March 31, 2014 | December 31, 2013 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 51,263 | $ | 65,002 | ||||
| Marketable securities | 74,270 | — | ||||||
| Restricted cash | 194 | 3,000 | ||||||
| Accounts receivable, net | 87,018 | 87,343 | ||||||
| Deferred tax assets | 123 | 6,118 | ||||||
| Prepaid expenses and other current assets | 18,531 | 17,194 | ||||||
| Total current assets | 231,399 | 178,657 | ||||||
| Property and equipment, net | 212,338 | 213,018 | ||||||
| Capitalized software costs, net | 35,625 | 29,987 | ||||||
| Purchased intangible assets, net | 161,172 | 168,364 | ||||||
| Goodwill | 198,049 | 198,049 | ||||||
| Investments and other assets | 8,229 | 8,321 | ||||||
| Total assets | $ | 846,812 | $ | 796,396 | ||||
| Liabilities & Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Line of credit | $ | 35,000 | $ | 35,000 | ||||
| Long-term debt | 15,000 | 15,000 | ||||||
| Accounts payable | 8,517 | 3,930 | ||||||
| Accrued compensation | 33,087 | 44,444 | ||||||
| Accrued expenses | 27,328 | 24,380 | ||||||
| Deferred revenue | 28,843 | 27,002 | ||||||
| Deferred tax liability | 13,933 | — | ||||||
| Total current liabilities | 161,708 | 149,756 | ||||||
| Deferred rent, net of current portion | 1,829 | 1,478 | ||||||
| Long-term debt, net of current portion | 170,000 | 173,750 | ||||||
| Deferred revenue, net of current portion | 52,586 | 53,172 | ||||||
| Long-term deferred tax liability, net | 24,430 | 21,421 | ||||||
| Other long-term liabilities | 6,861 | 5,511 | ||||||
| Total liabilities | 417,414 | 405,088 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively | — | — | ||||||
| Common stock, $0.01 par value: 125,000 shares authorized; 38,993 shares issued and 37,715 shares outstanding at March 31, 2014; 38,600 shares issued and 37,322 shares outstanding at December 31, 2013 | 390 | 387 | ||||||
| Additional paid-in capital | 381,358 | 380,967 | ||||||
| Treasury stock, at cost, 1,278 shares | (1,200 | ) | (1,200 | ) | ||||
| Accumulated other comprehensive income (loss) | 45,305 | (446 | ) | |||||
| Retained earnings | 3,545 | 11,600 | ||||||
| Total stockholders’ equity | 429,398 | 391,308 | ||||||
| Total liabilities and stockholders’ equity | $ | 846,812 | $ | 796,396 | ||||
4
athenahealth, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited, in thousands, except per share amounts)
| Three Months Ended March 31, | ||||||||
| 2014 | 2013 | |||||||
| Revenue: | ||||||||
| Business services | $ | 154,502 | $ | 121,463 | ||||
| Implementation and other | 8,533 | 4,133 | ||||||
| Total revenue | 163,035 | 125,596 | ||||||
| Expense: | ||||||||
| Direct operating | 72,148 | 53,185 | ||||||
| Selling and marketing | 43,227 | 32,922 | ||||||
| Research and development | 15,155 | 11,944 | ||||||
| General and administrative | 29,357 | 31,077 | ||||||
| Depreciation and amortization | 14,249 | 8,341 | ||||||
| Total expense | 174,136 | 137,469 | ||||||
| Operating loss | (11,101 | ) | (11,873 | ) | ||||
| Other (expense) income: | ||||||||
| Interest expense | (1,265 | ) | (164 | ) | ||||
| Other (expense) income | (171 | ) | 54 | |||||
| Total other expense | (1,436 | ) | (110 | ) | ||||
| Loss before income tax benefit | (12,537 | ) | (11,983 | ) | ||||
| Income tax benefit | 4,482 | 12,683 | ||||||
| Net (loss) income | $ | (8,055 | ) | $ | 700 | |||
| Net (loss) income per share – Basic | $ | (0.21 | ) | $ | 0.02 | |||
| Net (loss) income per share – Diluted | $ | (0.21 | ) | $ | 0.02 | |||
| Weighted average shares used in computing net (loss) income per share: | ||||||||
| Basic | 37,484 | 36,409 | ||||||
| Diluted | 37,484 | 37,744 | ||||||
5
athenahealth, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
| Three Months Ended March 31, | ||||||||
| 2014 | 2013 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net (loss) income | $ | (8,055 | ) | $ | 700 | |||
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 21,459 | 10,138 | ||||||
| Amortization of premium on investments | — | 84 | ||||||
| Deferred income tax | (4,605 | ) | (12,745 | ) | ||||
| Stock-based compensation expense | 12,351 | 13,658 | ||||||
| Other reconciling adjustments | 171 | (6 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | 325 | (7,512 | ) | |||||
| Prepaid expenses and other current assets | (1,627 | ) | (2,260 | ) | ||||
| Other long-term assets | (945 | ) | 73 | |||||
| Accounts payable | 3,913 | 1,985 | ||||||
| Accrued expenses | 2,951 | 4,199 | ||||||
| Accrued compensation | (13,529 | ) | (15,640 | ) | ||||
| Deferred revenue | 1,255 | 2,095 | ||||||
| Deferred rent | 402 | (309 | ) | |||||
| Net cash provided by (used in) operating activities | 14,066 | (5,540 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Capitalized software development costs | (11,057 | ) | (4,799 | ) | ||||
| Purchases of property and equipment | (5,325 | ) | (11,003 | ) | ||||
| Proceeds from sales and maturities of investments | — | 56,245 | ||||||
| Payments on acquisitions, net of cash acquired | — | (242,836 | ) | |||||
| Change in restricted cash | 2,806 | — | ||||||
| Net cash used in investing activities | (13,576 | ) | (202,393 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock under stock plans and warrants | 9,000 | 8,945 | ||||||
| Taxes paid related to net share settlement of stock awards | (19,464 | ) | (7,199 | ) | ||||
| Proceeds from line of credit | — | 105,000 | ||||||
| Payments on long-term debt | (3,750 | ) | — | |||||
| Net settlement of acquired company’s board of directors equity shares | — | (5,806 | ) | |||||
| Debt issuance costs | — | (275 | ) | |||||
| Net cash (used in) provided by financing activities | (14,214 | ) | 100,665 | |||||
| Effects of exchange rate changes on cash and cash equivalents | (15 | ) | 87 | |||||
| Net decrease in cash and cash equivalents | (13,739 | ) | (107,181 | ) | ||||
| Cash and cash equivalents at beginning of period | 65,002 | 154,988 | ||||||
| Cash and cash equivalents at end of period | $ | 51,263 | $ | 47,807 | ||||
6
athenahealth, Inc.
STOCK-BASED COMPENSATION
(Unaudited, in thousands)
Set forth below is a breakout of stock-based compensation impacting the Condensed Consolidated Statements of Income for the three months ended March 31, 2014, and 2013:
| Three Months Ended March 31, | |||||||
| 2014 | 2013 | ||||||
| Stock-based compensation charged to Condensed Consolidated Statements of Income: | |||||||
| Direct operating | $ | 2,596 | $ | 1,717 | |||
| Selling and marketing | 3,024 | 2,876 | |||||
| Research and development | 1,664 | 1,323 | |||||
| General and administrative | 5,066 | 7,742 | |||||
| Total stock-based compensation expense | 12,350 | 13,658 | |||||
| Amortization of capitalized stock-based compensation related to software development (1) | 399 | 156 | |||||
| Total | $ | 12,749 | $ | 13,814 | |||
| (1) | In addition, for the three months ended March 31, 2014, and 2013, $0.8 million and $0.4 million, respectively, of stock-based compensation was capitalized in the line item Capitalized Software Costs in the Condensed Consolidated Balance Sheet for which $0.4 million and $0.2 million, respectively, of amortization was included in the line item Depreciation and Amortization Expense in the Condensed Consolidated Statements of Income. |
athenahealth, Inc.
AMORTIZATION OF PURCHASED INTANGIBLE ASSETS
(Unaudited, in thousands)
Set forth below is a breakout of amortization of purchased intangible assets impacting the Condensed Consolidated Statements of Income for the three months ended March 31, 2014, and 2013:
| Three Months Ended March 31, | |||||||
| Amortization of purchased intangible assets allocated to: | 2014 | 2013 | |||||
| Direct operating | $ | 3,939 | $ | 1,740 | |||
| Selling and marketing | 3,151 | — | |||||
| Total amortization of purchased intangible assets | $ | 7,090 | $ | 1,740 | |||
7
athenahealth, Inc.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES
(Unaudited, in thousands, except per share amounts)
The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.
Please note that these figures may not sum exactly due to rounding.
Non-GAAP Adjusted Gross Margin
Set forth below is a presentation of our “Non-GAAP Adjusted Gross Profit” and “Non-GAAP Adjusted Gross Margin,” which represents Non-GAAP Adjusted Gross Profit as a percentage of total revenue.
| (unaudited, in thousands) | Three Months Ended | ||||||
| March 31, | |||||||
| 2014 | 2013 | ||||||
| Total revenue | $ | 163,035 | $ | 125,596 | |||
| Direct operating expense | 72,148 | 53,185 | |||||
| Total revenue less direct operating expense | 90,887 | 72,411 | |||||
| Add: Stock-based compensation allocated to direct operating expense | 2,596 | 1,717 | |||||
| Add: Amortization of purchased intangible assets allocated to direct operating expense | 3,939 | 1,740 | |||||
| Non-GAAP Adjusted Gross Profit | $ | 97,422 | $ | 75,868 | |||
| Non-GAAP Adjusted Gross Margin | 59.8 | % | 60.4 | % | |||
8
Non-GAAP Adjusted EBITDA
Set forth below is a reconciliation of our “Non-GAAP Adjusted EBITDA” and “Non-GAAP Adjusted EBITDA Margin,” which represents Non-GAAP Adjusted EBITDA as a percentage of total revenue.
| (unaudited, in thousands) | Three Months Ended | ||||||
| March 31, | |||||||
| 2014 | 2013 | ||||||
| Total Revenue | $ | 163,035 | $ | 125,596 | |||
| GAAP net (loss) income | (8,055 | ) | 700 | ||||
| Add: Benefit from income taxes | (4,482 | ) | (12,683 | ) | |||
| Add: Total other expense | 1,436 | 110 | |||||
| Add: Stock-based compensation expense | 12,350 | 13,658 | |||||
| Add: Depreciation and amortization | 14,249 | 8,341 | |||||
| Add: Amortization of purchased intangible assets | 7,090 | 1,740 | |||||
| Add: Integration and transaction costs | — | 3,794 | |||||
| Add: Non-tax deductible transaction costs | — | 1,915 | |||||
| Non-GAAP Adjusted EBITDA | $ | 22,588 | $ | 17,575 | |||
| Non-GAAP Adjusted EBITDA Margin | 13.9 | % | 14.0 | % | |||
Non-GAAP Adjusted Operating Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin,” which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.
| (unaudited, in thousands) | Three Months Ended | ||||||
| March 31, | |||||||
| 2014 | 2013 | ||||||
| Total revenue | $ | 163,035 | $ | 125,596 | |||
| GAAP net (loss) income | (8,055 | ) | 700 | ||||
| Add: Benefit from income taxes | (4,482 | ) | (12,683 | ) | |||
| Add: Total other expense | 1,436 | 110 | |||||
| Add: Stock-based compensation expense | 12,350 | 13,658 | |||||
| Add: Amortization of capitalized stock-based compensation related to software development | 399 | 156 | |||||
| Add: Amortization of purchased intangible assets | 7,090 | 1,740 | |||||
| Add: Integration and transaction costs | — | 3,794 | |||||
| Add: Non-tax deductible transaction costs | — | 1,915 | |||||
| Non-GAAP Adjusted Operating Income | $ | 8,738 | $ | 9,390 | |||
| Non-GAAP Adjusted Operating Income Margin | 5.4 | % | 7.5 | % | |||
9
Non-GAAP Adjusted Net Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Net Income” and “Non-GAAP Adjusted Net Income per Diluted Share.”
| (unaudited, in thousands) | Three Months Ended | ||||||
| March 31, | |||||||
| 2014 | 2013 | ||||||
| GAAP net (loss) income | $ | (8,055 | ) | $ | 700 | ||
| Add: Stock-based compensation expense | 12,350 | 13,658 | |||||
| Add: Amortization of capitalized stock-based compensation related to software development | 399 | 156 | |||||
| Add: Amortization of purchased intangible assets | 7,090 | 1,740 | |||||
| Add: Integration and transaction costs | — | 3,794 | |||||
| Sub-total of tax deductible items | 19,839 | 19,348 | |||||
| Less: Tax impact of tax deductible items (1) | (7,936 | ) | (7,739 | ) | |||
| Add: Non-tax deductible transaction costs | — | 1,915 | |||||
| Add: Tax impact resulting from applying non-GAAP tax rate (2) | 533 | — | |||||
| Non-GAAP Adjusted Net Income | $ | 4,381 | $ | 14,224 | |||
| Weighted average shares - diluted | 37,484 | 37,744 | |||||
| Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.12 | $ | 0.38 | |||
| (1) | Tax impact calculated using a statutory tax rate of 40%. |
| (2) | Represents adjusting the GAAP net loss at a non-GAAP tax rate of 40%. For 2014, we are using a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income could result in a volatile GAAP effective tax rate. If this approach had been used in 2013, the tax impact from applying a non-GAAP tax rate would have been ($8,656) and our Q1 2013 Non-GAAP Adjusted Net Income per Diluted Share would have been $0.15 or a reduction of $0.23. |
10
| (unaudited, in thousands) | Three Months Ended | ||||||
| March 31, | |||||||
| 2014 | 2013 | ||||||
| GAAP net (loss) income per share - diluted | $ | (0.21 | ) | $ | 0.02 | ||
| Add: Stock-based compensation expense | 0.33 | 0.36 | |||||
| Add: Amortization of capitalized stock-based compensation related to software development | 0.01 | — | |||||
| Add: Amortization of purchased intangible assets | 0.19 | 0.05 | |||||
| Add: Integration and transaction costs | — | 0.10 | |||||
| Sub-total of tax deductible items | 0.53 | 0.51 | |||||
| Less: Tax impact of tax deductible items (1) | (0.21 | ) | (0.21 | ) | |||
| Add: Non-tax deductible transaction costs | — | 0.05 | |||||
| Add: Tax impact resulting from applying non-GAAP tax rate (2) | 0.01 | — | |||||
| Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.12 | $ | 0.38 | |||
| Weighted average shares - diluted | 37,484 | 37,744 | |||||
| (1) | Tax impact calculated using a statutory tax rate of 40%. |
| (2) | Represents adjusting the GAAP net loss at a non-GAAP tax rate of 40%. For 2014, we are using a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income could result in a volatile GAAP effective tax rate. If this approach had been used in 2013, the tax impact from applying a non-GAAP tax rate would have been ($8,656) and our Q1 2013 Non-GAAP Adjusted Net Income per Diluted Share would have been $0.15 or a reduction of $0.23. |
11
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of athenahealth and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
Management defines “Non-GAAP Adjusted Gross Profit” as total revenue, less direct operating expense, plus (1) stock-based compensation expense allocated to direct operating expense and (2) amortization of purchased intangible assets allocated to direct operating expense, and “Non-GAAP Adjusted Gross Margin” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in our ability to generate income from ongoing business operations.
Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP net income before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, depreciation and amortization, amortization of purchased intangible assets, integration costs, and transaction costs and “Non-GAAP Adjusted EBITDA Margin” as Non-GAAP Adjusted EBITDA as a percentage of total revenue. Management defines “Non-GAAP Adjusted Operating Income” as the sum of GAAP net income before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration costs, and transaction costs and “Non-GAAP Adjusted Operating Income Margin” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “Non-GAAP Adjusted Net Income” as the sum of GAAP net income before stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration costs, transaction costs, any tax impact related to these preceding items, and an adjustment to the tax provision for the non-GAAP tax rate and “Non-GAAP Adjusted Net Income per Diluted Share” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.
12
Management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:
• | Stock-based compensation expense and amortization of capitalized stock-based compensation related to software development — excluded because these are non-cash expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. |
• | Amortization of purchased intangible assets — purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. |
• | Integration costs — integration costs are the severance and retention bonuses for certain employees relating to the Epocrates acquisition. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. |
• | Transaction costs — transaction costs are non-recurring costs related to specific transactions. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. |
| • | Non-GAAP tax rate — For 2014, we are using a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income could result in a volatile GAAP effective tax rate. |
13